- Home
- ANNX vs HUMA Comparison
ANNX vs HUMA Comparison
Compare ANNX & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- HUMA
- Stock Information
- Founded
- ANNX 2011
- HUMA 2004
- Country
- ANNX United States
- HUMA United States
- Employees
- ANNX N/A
- HUMA N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- ANNX Health Care
- HUMA Health Care
- Exchange
- ANNX Nasdaq
- HUMA Nasdaq
- Market Cap
- ANNX 253.8M
- HUMA 250.2M
- IPO Year
- ANNX 2020
- HUMA N/A
- Fundamental
- Price
- ANNX $3.09
- HUMA $1.65
- Analyst Decision
- ANNX Strong Buy
- HUMA Strong Buy
- Analyst Count
- ANNX 4
- HUMA 7
- Target Price
- ANNX $13.00
- HUMA $10.57
- AVG Volume (30 Days)
- ANNX 2.4M
- HUMA 5.5M
- Earning Date
- ANNX 11-13-2025
- HUMA 11-07-2025
- Dividend Yield
- ANNX N/A
- HUMA N/A
- EPS Growth
- ANNX N/A
- HUMA N/A
- EPS
- ANNX N/A
- HUMA N/A
- Revenue
- ANNX N/A
- HUMA $818,000.00
- Revenue This Year
- ANNX N/A
- HUMA N/A
- Revenue Next Year
- ANNX N/A
- HUMA $1,686.52
- P/E Ratio
- ANNX N/A
- HUMA N/A
- Revenue Growth
- ANNX N/A
- HUMA N/A
- 52 Week Low
- ANNX $1.29
- HUMA $1.15
- 52 Week High
- ANNX $7.85
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- ANNX 60.42
- HUMA 47.24
- Support Level
- ANNX $2.91
- HUMA $1.69
- Resistance Level
- ANNX $3.38
- HUMA $2.55
- Average True Range (ATR)
- ANNX 0.24
- HUMA 0.18
- MACD
- ANNX 0.02
- HUMA 0.05
- Stochastic Oscillator
- ANNX 61.87
- HUMA 9.69
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.